Crohn’s disease of the small intestine

被引:0
作者
Robert Burakoff
机构
[1] Washington Hospital Center,Section of Gastroenterology
关键词
Infliximab; Metronidazole; Budesonide; Main Side Effect; Main Drug Interaction;
D O I
10.1007/s11938-000-0062-3
中图分类号
学科分类号
摘要
Crohn’s disease of the small intestine is a chronic relapsing disease that requires all the knowledge and ingenuity of the gastroenterologist to successfully treat the disease and the patient.For mild to moderate disease, the first line of therapy is to utilize maximum doses of mesalamine to achieve a remission.If the patient relapses, the maximum dose of mesalamine required to achieve remission should be continued.If the disease relapses despite maximum mesalamine, antibiotics should be tried (before prescribing corticosteroids) using ciprofloxacin 500 mg b.i.d., alone or in combination with metronidazole 250 mg q.i.d. for 2 to 3 weeks. If successful, antibiotics can be slowly tapered off.If antibiotics are unsuccessful, one may try elemental diet for 2 weeks before starting corticosteroids.For moderate to severe Crohn’s disease, begin 40 mg of prednisone. After 2 weeks, taper slowly and start 6-MP or azathioprine, which can be used for several years.If the disease recurs on 6-MP or azathioprine, or prior to 6-MP or azathioprine having a chance to be effective, give an IV infusion of Infliximab, which can be repeated at 4 to 8 weeks after the initial infusion.If the patient continues to be unwell, surgery should be contemplated.
引用
收藏
页码:59 / 68
页数:9
相关论文
共 81 条
[1]  
Singleton JW(1993)Mesalamine capsules for the treatment of active Crohn’s disease: Results of A 16 week trial Gastroenterology 104 1293-1300
[2]  
Hanauer SB(1996)Mesalamine in Crohn’s disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenances Gastroenterology 110 688-693
[3]  
Getnick G(1994)A randomized, double blind, placebo controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s and ileocolitis J Clin Gastroenterol 19 278-282
[4]  
Modigliani R(1992)Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn’s disease Gastroenterology 103 363-368
[5]  
Colombel JF(1997)Mesalamine in the maintenance treatment of Crohn’s disease: A meta-analysis adjusted for confounding variables Gastroenterology 113 1465-1473
[6]  
Dupas JL(1995)Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn’s disease Gastroenterology 109 404-413
[7]  
Tremaine WJ(1994)Oral budesonide for active Crohn’s disease N Engl J Med 331 836-841
[8]  
Schroder KW(1998)Treatment of Crohn’s disease at the turn of the century N Engl J Med 339 401-402
[9]  
Harrison JM(1996)Oral budesonide as maintenance treatment for Crohn’s disease: A placebo-controlled, dose ranging study Gastroenterology 110 45-51
[10]  
Zinsmeister AR(1995)Azathioprine and 6-MP in Crohn’s disease: A meta-analysis Ann Intern Med 122 132-142